VIDEO: Early reduction in urine albumin-to-creatinine ratio with finerenone
In this video, George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about new subgroup analysis of the FIDELIO-DKD trial, which was released at ASN Kidney Week.
Researchers studied how urine albumin-to-creatinine ratio reduction correlates with kidney and cardiovascular protection.
In the randomized controlled trial, 5,674 patients with type 2 diabetes and eGFR of 25 to <75 mL/min/1.73 m2 received finerenone or placebo. Researchers found 31% greater reduction in the urine albumin-to-creatinine ratio from baseline to 4 months for patients in the finerenone group compared with patients who received placebo. Additionally, the reduction in urine albumin-to-creatinine ratio from baseline to 4 months was associated with a reduction in risk for kidney outcomes.
“In short, the take-home message is number one —to echo the National Kidney Foundation —you need to be measuring albuminuria or you don’t know what stage kidney disease you have. More importantly in this sub-analysis, the level of albuminuria, which normally dictated how bad the outcome would be, in the presence of finerenone was markedly reduced and better tolerated. I think is an important observation to be made,” he said.
Collapse
Agarwal R, et al. Poster PO2528. Presented at: ASN Kidney Week. Nov. 4-7, 2021 (virtual meeting).
Read more about